BACKGROUND AND OBJECTIVES: The aim of the present study was to examine the association between the expression of human epidermal receptor (HER) 1, HER3, and HER4 and pathologic complete response (pCR) in HER2-positive patients treated with trastuzumab-containing neo-adjuvant chemotherapy. METHODS: Immunohistochemical analyses of HER1, HER3, and HER4 were performed using tumor specimens obtained from patients treated with trastuzumab-containing neoadjuvant chemotherapy. The staining intensity of each biomarker was evaluated, and the correlations between the immunohistochemical profiles and pCR were examined. RESULTS: The present study included 44 patients with HER2-positive breast cancer treated with trastuzumab-containing neo-adjuvant chemotherapy. Seventeen patients achieved a pCR. The expressions of HER1, HER3, and HER4 were observed in 18.2%, 27.3%, and 18.2% of the specimens, respectively. A marginally significant negative correlation between the expression of HER1 and pCR was observed, irrespective of the expression of HER3 and HER4, whereas the expressions of HER3 and HER4 were not significantly correlated with pCR. CONCLUSION: The expression of HER1 might be an independently negative predictor of pCR in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. (c) 2010 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVES: The aim of the present study was to examine the association between the expression of humanepidermal receptor (HER) 1, HER3, and HER4 and pathologic complete response (pCR) in HER2-positive patients treated with trastuzumab-containing neo-adjuvant chemotherapy. METHODS: Immunohistochemical analyses of HER1, HER3, and HER4 were performed using tumor specimens obtained from patients treated with trastuzumab-containing neoadjuvant chemotherapy. The staining intensity of each biomarker was evaluated, and the correlations between the immunohistochemical profiles and pCR were examined. RESULTS: The present study included 44 patients with HER2-positive breast cancer treated with trastuzumab-containing neo-adjuvant chemotherapy. Seventeen patients achieved a pCR. The expressions of HER1, HER3, and HER4 were observed in 18.2%, 27.3%, and 18.2% of the specimens, respectively. A marginally significant negative correlation between the expression of HER1 and pCR was observed, irrespective of the expression of HER3 and HER4, whereas the expressions of HER3 and HER4 were not significantly correlated with pCR. CONCLUSION: The expression of HER1 might be an independently negative predictor of pCR in HER2-positive breast cancerpatients treated with trastuzumab-containing neoadjuvant chemotherapy. (c) 2010 Wiley-Liss, Inc.
Authors: Jamunarani Veeraraghavan; Carmine De Angelis; Jorge S Reis-Filho; Tomás Pascual; Aleix Prat; Mothaffar F Rimawi; C Kent Osborne; Rachel Schiff Journal: Breast Date: 2017-07-04 Impact factor: 4.380
Authors: Agnieszka Adamczyk; Aleksandra Grela-Wojewoda; Małgorzata Domagała-Haduch; Aleksandra Ambicka; Agnieszka Harazin-Lechowska; Anna Janecka; Ida Cedrych; Kaja Majchrzyk; Anna Kruczak; Janusz Ryś; Joanna Niemiec Journal: J Cancer Date: 2017-01-01 Impact factor: 4.207
Authors: Bryce P Portier; Eugen C Minca; Zhen Wang; Christopher Lanigan; Aaron M Gruver; Erinn Downs-Kelly; G Thomas Budd; Raymond R Tubbs Journal: Oncotarget Date: 2013-10